Sir Gregory Winter, a prominent British molecular biologist will visit Sydney on January 24 to speak to investors about the potential of Biosceptre International, a biotechnology company based in Australia.

Biosceptre International is a public biotechnology company that is developing and commercializing antibody technologies in the diagnosis and treatment of cancer.

"We believe we have developed potentially game-changing technology,"
said Chief Executive Officer of Biosceptre, Dr Cliff Holloway in a statement.

"Having attained a strong patent portfolio around our technology,
Biosceptre is now transitioning from the research to the development
phase. The company is seeking additional capital to take our lead
antibody products through to clinical evaluation. These antibodies have
shown great promise in the laboratory and have the potential to treat a
range of cancer indications and address the significant unmet need in
the quest for successful cancer therapies."

Sir Gregory Winter will discuss the merits of Biosceptre and the evolution of antibody therapeutics to the company's investors. Biosceptre's technology is based on the discovery of a novel cancer biomarker known as "non-functional P2X7 (nf-P2X7) which has been indentified in over 20 cancer indication tests today. The company is aiming to develop nf- P2X7 as a therapeutic target and to develop antibody products for cancer treatment.

Sir Gregory Winter is a pioneer of therapeutic monoclonal antibodies. He invented the technique that humanized antibodies using phage display for therapeutic use. He is a Fellow of Trinity College, Cambridge and has been named the next Master. He is also Deputy Director of the Laboratory of Molecular Biology, Medical Research Council and Head of the Division of Protein and Nucleic Acids Chemistry.

Cancer is the second leading cause of death worldwide, and the disease with the highest unmet medical need. Biosceptre's technology has the potential to change the way cancer is diagnosed and treated worldwide, offering unparalleled benefits to patients, doctors and investors alike.